Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2018

Open Access 01-12-2018 | Case report

Substance-induced anxiety disorder after one dose of 3,4-methylenedioxymethamphetamine: a case report

Authors: Kaeley Kaplan, Fiona Kurtz, Kelly Serafini

Published in: Journal of Medical Case Reports | Issue 1/2018

Login to get access

Abstract

Background

In this report, we describe a case of a patient with substance-induced anxiety disorder occurring after a single dose of 3,4-methylenedioxymethamphetamine. Furthermore, we describe the use and efficacy of the Primary Care Behavioral Health model, a collaborative approach to integrative primary mental health care, in evaluating and treating this rare mental health disorder.

Case presentation

Three days following ingestion of one dose of 3,4-methylenedioxymethamphetamine, a 35-year-old Hispanic man with no significant prior mental health history and no history of prior 3,4-methylenedioxymethamphetamine use presented to our hospital with severe, acute anxiety and panic symptoms. He was initially treated with a combination of behavioral therapy and the serotonin agonist buspirone. Buspirone ultimately proved ineffective, so it was discontinued in favor of the selective serotonin reuptake inhibitor sertraline. While awaiting the pharmacological onset of sertraline, the patient worked with a behavioral health consultant, who provided psychoeducation on the experience of panic, building relaxation skills, and modifying maladaptive thought patterns. Enhanced communication between the primary care provider and behavioral health consultant facilitated the planning and enactment of the patient’s care plan. Approximately 2.5 months after his initial ingestion of 3,4-methylenedioxymethamphetamine, the patient’s symptoms subsided. This improvement was attributed to the combination of the behavioral health intervention and sertraline at a dose of 50 mg daily. Six months after 3,4-methylenedioxymethamphetamine ingestion, the patient began to gradually taper sertraline and has had no resurgence of anxiety symptoms to date.

Conclusions

Our patient’s case not only demonstrates a rare presentation of 3,4-methylenedioxymethamphetamine-induced anxiety disorder but also provides support for the use of the Primary Care Behavioral Health model to deliver individualized, timely mental health care in a primary care setting.
Literature
1.
go back to reference Morgan MJ. Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology. 2000;152:230–48.CrossRefPubMed Morgan MJ. Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology. 2000;152:230–48.CrossRefPubMed
2.
go back to reference United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. National survey on drug use and health, 2014. Ann Arbor: Inter-university Consortium for Political and Social Research; 2016. https://doi.org/10.3886/ICPSR36361.v1. Accessed 9 July 2017. United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. National survey on drug use and health, 2014. Ann Arbor: Inter-university Consortium for Political and Social Research; 2016. https://​doi.​org/​10.​3886/​ICPSR36361.​v1. Accessed 9 July 2017.
3.
go back to reference Solowji N, Hall W, Lee N. Recreational MDMA use in Sydney: a profile of ‘ecstasy’ users and their experience with the drug. Br J Addict. 1992;87:1161–72.CrossRef Solowji N, Hall W, Lee N. Recreational MDMA use in Sydney: a profile of ‘ecstasy’ users and their experience with the drug. Br J Addict. 1992;87:1161–72.CrossRef
4.
go back to reference Verheyden SL, Henry JA, Curran HV. Acute, sub-acute and long-term subjective consequences of ‘ecstasy’ (MDMA) consumption in 430 regular users. Human Psychopharmacol. 2003;18:507–17.CrossRef Verheyden SL, Henry JA, Curran HV. Acute, sub-acute and long-term subjective consequences of ‘ecstasy’ (MDMA) consumption in 430 regular users. Human Psychopharmacol. 2003;18:507–17.CrossRef
5.
go back to reference McCann UD, Ricuarte GA. MDMA (“Ecstasy”) and panic disorder: induction by a single dose. Biol Psychiatry. 1992;32:950–3.CrossRefPubMed McCann UD, Ricuarte GA. MDMA (“Ecstasy”) and panic disorder: induction by a single dose. Biol Psychiatry. 1992;32:950–3.CrossRefPubMed
6.
go back to reference Viava G, Boss V, Bailly D, Thomas P, Lestavel P, Goudemand M. An “accidental” acute psychosis with ecstasy use. J Psychoactive Drugs. 2001;33:95–8.CrossRef Viava G, Boss V, Bailly D, Thomas P, Lestavel P, Goudemand M. An “accidental” acute psychosis with ecstasy use. J Psychoactive Drugs. 2001;33:95–8.CrossRef
7.
go back to reference Green AR, Mechan AO, Elliot JM, O’Shea E, Colado MI. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”). Pharmacol Rev. 2003;55:463–508.CrossRefPubMed Green AR, Mechan AO, Elliot JM, O’Shea E, Colado MI. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”). Pharmacol Rev. 2003;55:463–508.CrossRefPubMed
8.
go back to reference Ricaurte GA, DeLanney LE, Irwin I, Langston JW. Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration. Brain Res. 1998;446:165–8.CrossRef Ricaurte GA, DeLanney LE, Irwin I, Langston JW. Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration. Brain Res. 1998;446:165–8.CrossRef
9.
go back to reference Lowry CA, Johnson PL, Hay-Schmidt A, Mikkelsen J, Shekhar A. Modulation of anxiety circuits by serotonergic systems. Stress. 2005;8:233–46.CrossRefPubMed Lowry CA, Johnson PL, Hay-Schmidt A, Mikkelsen J, Shekhar A. Modulation of anxiety circuits by serotonergic systems. Stress. 2005;8:233–46.CrossRefPubMed
10.
go back to reference Bryan CJ, Morrow C, Appolonio KK. Impact of behavioral health consultant interventions on patient symptoms and functioning in an integrated family medicine clinic. J Clin Psychol. 2009;65:281–93.CrossRefPubMed Bryan CJ, Morrow C, Appolonio KK. Impact of behavioral health consultant interventions on patient symptoms and functioning in an integrated family medicine clinic. J Clin Psychol. 2009;65:281–93.CrossRefPubMed
11.
go back to reference Gatchel RJ, Oordt MS. Clinical health psychology and primary care: practical advice and clinical guidance for successful collaboration. Washington, DC: American Psychological Association; 2003.CrossRef Gatchel RJ, Oordt MS. Clinical health psychology and primary care: practical advice and clinical guidance for successful collaboration. Washington, DC: American Psychological Association; 2003.CrossRef
12.
go back to reference Kessler RC, Demler O, Frank RG, Olfson M, Pincus HA, Walters EE, Wang P, Wells KB, Zaslavsky AM. Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med. 2005;352:2515–23.CrossRefPubMedPubMedCentral Kessler RC, Demler O, Frank RG, Olfson M, Pincus HA, Walters EE, Wang P, Wells KB, Zaslavsky AM. Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med. 2005;352:2515–23.CrossRefPubMedPubMedCentral
13.
go back to reference Narrow WE, Regier DA, Rae DS, Manderscheid RW, Locke BZ. Use of services by persons with mental and addictive disorders: findings from the National Institute of Mental Health Epidemiologic Catchment Area Program. Arch Gen Psychiatry. 1993;50:95–107.CrossRefPubMed Narrow WE, Regier DA, Rae DS, Manderscheid RW, Locke BZ. Use of services by persons with mental and addictive disorders: findings from the National Institute of Mental Health Epidemiologic Catchment Area Program. Arch Gen Psychiatry. 1993;50:95–107.CrossRefPubMed
14.
go back to reference Hunter CL, Goodie JL. Operational and clinical components for integrated-collaborative behavioral healthcare in the patient-centered medical home. Fam Syst Health. 2010;28:308–21.CrossRefPubMed Hunter CL, Goodie JL. Operational and clinical components for integrated-collaborative behavioral healthcare in the patient-centered medical home. Fam Syst Health. 2010;28:308–21.CrossRefPubMed
15.
go back to reference Spitzer RL, Kroenke K, Williams JB, Löwe JB. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166:1092–7.CrossRefPubMed Spitzer RL, Kroenke K, Williams JB, Löwe JB. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166:1092–7.CrossRefPubMed
Metadata
Title
Substance-induced anxiety disorder after one dose of 3,4-methylenedioxymethamphetamine: a case report
Authors
Kaeley Kaplan
Fiona Kurtz
Kelly Serafini
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2018
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/s13256-018-1670-7

Other articles of this Issue 1/2018

Journal of Medical Case Reports 1/2018 Go to the issue